USFDA Concludes Surveillance Inspection at Shilpa Medicare's Unit VII Analytical Facility
Shilpa Medicare Ltd 路 Others (Uncategorized) 路 19 Sept 2026, 12:24 am
USFDA Concludes Surveillance Inspection at Shilpa Medicare's Unit VII Analytical Facility The USFDA concluded a surveillance inspection at Shilpa Medicare's Unit VII Analytical Services Division in Hyderabad on 18th Sep'26 with one procedural observation. The observation is neither a repeat issue nor related to data integrity. The company plans to submit a response with corrective and preventive actions within the stipulated timeline and expects no material impact on current business operations or existing supplies from the facility.
Original exchange filing (PDF)
More announcements from Shilpa Medicare Ltd
- Q2FY27 Earnings Conference Call 05 November 2026 路 11 Nov 2026
- Audio link of the Investor Conference call for the quarter ended 30 September 2026. 路 06 Nov 2026
- Update on Corporate Insolvency Resolution Process of FTF Pharma Private Limited, a Wholly Owned Subsidiary of Shilpa Medicare Limited 路 05 Nov 2026
- Investor Presentation for the Quarter and Half year ended 30 September 2026 路 05 Nov 2026
- Outcome of the Board Meeting 路 05 Nov 2026
- Shilpa Medicare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 05 Nov 2026
- Financial Results for the Quarter and Half year ended 30 September 2026 路 05 Nov 2026
- SHILPA MEDICARE LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 05 Nov 2026
